key: cord-0847841-foopvh5z
authors: Gaebler, Christian; Wang, Zijun; Lorenzi, Julio C. C.; Muecksch, Frauke; Finkin, Shlomo; Tokuyama, Minami; Ladinsky, Mark; Cho, Alice; Jankovic, Mila; Schaefer-Babajew, Dennis; Oliveira, Thiago Y.; Cipolla, Melissa; Viant, Charlotte; Barnes, Christopher O.; Hurley, Arlene; Turroja, Martina; Gordon, Kristie; Millard, Katrina G.; Ramos, Victor; Schmidt, Fabian; Weisblum, Yiska; Jha, Divya; Tankelevich, Michael; Yee, Jim; Shimeliovich, Irina; Robbiani, Davide F.; Zhao, Zhen; Gazumyan, Anna; Hatziioannou, Theodora; Bjorkman, Pamela J.; Mehandru, Saurabh; Bieniasz, Paul D.; Caskey, Marina; Nussenzweig, Michel C.
title: Evolution of Antibody Immunity to SARS-CoV-2
date: 2020-11-05
journal: bioRxiv
DOI: 10.1101/2020.11.03.367391
sha: ec9bc47cf086cbe61affb528f0af7d8690932950
doc_id: 847841
cord_uid: foopvh5z

SARS-CoV-2 has infected 47 million individuals and is responsible for over 1.2 million deaths to date. Infection is associated with development of variable levels of antibodies with neutralizing activity that can protect against infection in animal models. Antibody levels decrease with time, but the nature and quality of the memory B cells that would be called upon to produce antibodies upon re-infection has not been examined. Here we report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection. We find that IgM, and IgG anti-SARS-CoV-2 spike protein receptor binding domain (RBD) antibody titers decrease significantly with IgA being less affected. Concurrently, neutralizing activity in plasma decreases by five-fold in pseudotype virus assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B cells display clonal turnover after 6.2 months, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response. Analysis of intestinal biopsies obtained from asymptomatic individuals 3 months after COVID-19 onset, using immunofluorescence, electron tomography or polymerase chain reaction, revealed persistence of SARS-CoV-2 in the small bowel of 7 out of 14 volunteers. We conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.

. In addition, the overall clonal composition of the memory compartment differed at the 119 two time points in all individuals examined (Fig. 2d) . Forty-three expanded clones that were 120 present at the earlier time point were not detectable after 6.2 months while 22 new expanded clones 121 appeared. In addition, the relative distribution of clones that appeared at both time points also 122 varied. For example, the dominant clones in COV21 and COV57 representing 9.0% and 16.7% of 123 all sequences, respectively, were reduced to 1.1% and 1.9% of all sequences after 6.2 months (Fig. 124 2d and Supplementary Table 3 ). We conclude that while the magnitude of the RBD-specific 125 memory B cell compartment is conserved between 1.3 and 6.2 months after SARS-CoV-2 126 infection, there is significant clonal turnover and antibody sequence evolution, consistent with 127 prolonged germinal center reactions. 128 129 One hundred and twenty-two representative antibodies from the 6.2-month time point were tested 130 for reactivity to RBD (Supplementary Table 4 ). The antibodies that were evaluated included: (1) 131 49 that were randomly selected from those that appeared only once; (2) 23 that appeared as singles together, the mean ELISA EC50 was not significantly different at the two time points (Fig. 3a , 137

Supplementary Table 4 and 1 ). However, comparison of the antibodies that were present at both 138 time points revealed a significant improvement of the EC50 after 6.2 months (p= 0.0227, Fig. 3b  139 and Extended data Fig.8a) . 140

To determine whether the antibodies exhibiting altered RBD binding also show increased 165 neutralizing breadth, we tested 5 representative antibody pairs recovered at the two time points 166 against HIV-1 viruses pseudotyped with E484G, Q493R, and R346S mutant spike proteins (Fig.  167 4c, Supplementary Table 6) . Notably, the Q493R and E484G pseudotyped viruses were resistant 168 to neutralization by C144; in contrast, its 6.2-month clonal derivative C051 neutralized both 169 variants with IC50 values of 4.7 and 3.1 ng/ml respectively (Fig. 4c-d) . Similarly, R346S 170 pseudotyped viruses were resistant to C032, but a 6.2-month clonal derivative C080 neutralized 171 this variant with an IC50 of 5.3 ng/ml ( Table 7 ). Clinically approved nasopharyngeal swab PCR assays were 186 negative in all 14 individuals at the time of biopsy. However, biopsy samples from 3 of the 14 187 participants produced PCR amplicons that were sequence verified as SARS-CoV-2 (Methods and 188 Supplementary Table 7) . Immunostaining was performed to determine whether viral protein was 189 also detectable in upper and lower GI tract, with de-identified biopsies from individuals pre-dating 190 the pandemic (n=10) serving as controls. ACE2 and SARS-CoV-2 N protein was detected in 191 intestinal enterocytes in 5 of 14 individuals but not in historic control samples ( Fig. 5a- Neutralizing monoclonal antibodies obtained from individuals during the early convalescence 212 period showed remarkably low levels of somatic mutations that some investigators attributed to 213 defects in germinal center formation 9,10,12,34-37, . Our data indicate that the anti-SARS-CoV-2 214 memory B cell response evolves during the first 6 months after infection, with accumulation of Ig 215 somatic mutations, and production of antibodies with increased neutralizing breadth and potency. 216

Persistent antibody evolution occurs in germinal centers and requires that B cells are exposed to 217 antigen trapped in the form of immune complexes on follicular dendritic cells 38 . This form of 218 antigen can be long-lived because follicular dendritic cells do not internalize immune complexes. 219

In addition, even small amounts of persistent viral replication could contribute antigen to fuel 220 antibody evolution. The observation that SARS-CoV-2 remains detectable in the small intestinal 221 epithelium even 3 months after infection is consistent with the relative persistence of anti-RBD 222

IgA antibodies and continued antibody evolution. However, the prevalence, clinical significance, 223 and potential infectivity of residual SARS-CoV-2 in intestinal enterocytes remain to be 224 determined. 225 226 Memory responses are responsible for protection from re-infection and are essential for effective 227 vaccination. The observation that memory B cell responses do not decay after 6.2 months, but 228 instead continue to evolve, is strongly suggestive that individuals who are infected with SARS-229

CoV-2 could mount a rapid and effective response to the virus upon re-exposure. Relative change in plasma antibody levels between 1.3 and 6.2 months for anti-RBD IgM, IgG, 241

IgA and anti-N total Ig, respectively. f-i, Relative change in antibody levels between 1.3 and 6.2 242 months plotted against the corresponding antibody levels at 1.3 months. f, Anti-RBD IgM. r = -243 0.83, p <0.0001. g, Anti-RBD IgG. r = -0.76, p <0.0001. h, Anti-RBD IgA. r = -0.67, p <0.0001. 244 i, Anti-N total antibodies. r = -0.23, p = 0.039. j. Ranked average half-maximal inhibitory plasma 245 neutralizing titer (NT50) at 1.3 months (blue) and 6.2 months (red) for the 87 individuals studied. 246 k. Graph shows NT50 for plasma collected at 1.3 and 6.2 months p <0.0001. l. Relative change in 247 plasma neutralizing titers between 1.3 and 6.2 months plotted against the corresponding titers at 248 were assigned based on their V and J genes using in-house R and Perl scripts (Extended data Fig.4) . 489

All scripts and the data used to process antibody sequences are publicly available on GitHub 490 (https://github.com/stratust/igpipeline). We used 532 heavy chain CDR3 amino acid sequences from this study and 22,654,256 IGH CDR3 513 sequences from the public database of memory B cell receptor sequences 53 . The Shapiro-Wilk 514 test was used to determine whether the GRAVY scores are normally distributed. The GRAVY 515 scores from all 532 IGH CDR3 amino acid sequences from this study were used to perform the 516 test and 5,000 GRAVY scores of the sequences from the public database were randomly selected. 517

The Shapiro-Wilk P values were 6.896 × 10−3 and 2.217 × 10−6 for sequences from this study 518 and the public database, respectively, indicating that the data were not normally distributed. 519 Therefore, we used the Wilcoxon nonparametric test to compare the samples, which indicated a 520 difference in hydrophobicity distribution (P = 5 × 10−6) (Extended data Fig.7) . 521 522 Heatmap of log2 relative fold change in EC50 against the indicated RBD mutants for antibody 523 clonal pairs obtained at 1.3 and 6.2 months ( Fig.3e and Extended data Fig. 8k) Endoscopically obtained mucosal biopsies were formalin fixed and paraffin embedded. Sections 529 (5µm) were cut, dewaxed in xylene, and rehydrated in graded alcohol and phosphate-buffered 530 saline (PBS). Heat-induced epitope retrieval was performed in target retrieval solution (Dako, 531 S1699) using a commercial pressure cooker. Slides were then cooled to room temperature, washed 532 in PBS and permeabilized for 30 minutes in 0.1% tritonX-100 in PBS. Non-specific binding was 533 blocked with 10% goat serum (Invitrogen, 50062Z) for 1 hour at room temperature. Sections were 534 then incubated with a combination of primary antibodies diluted in blocking solution overnight at 535 4°C. Slides were washed 3 times in PBS and then incubated in secondary antibody and 4′,6-536 diamidino-2-phenylindole (1ug/mL) for 1 hour at room temperature. Sections were washed in PBS 537

Controls included, omitting primary antibody (no primary 995 control), or substituting primary 539 antibodies with non-reactive antibodies of the same isotype (isotype control). A Nikon Eclipse Ni 540 microscope and digital SLR camera (Nikon, DS-Qi2) was used to visualize and image the tissue. 541

The antibody used to stain sections for N protein was raised in rabbits against SARS-CoV N and 543 is cross-reactive with SARS-CoV-2 N protein 54 

To determine if SARS-CoV-2 RNA is present in the gastrointestinal tract we isolated 548 RNA from endoscopically obtained mucosal biopsies using Direct-zol miniprep kit (Zymo Tissues samples were fixed with 3% glutaraldehyde to meet biosafety requirements. Tissues were 562 rinsed with cold 0.1M sodium cacodylate trihydrate + 5% sucrose and further dissected to block 563 sizes sufficient for embedding and sectioning. Tissues were postfixed for 1 h with cold 2% osmium 564 tetroxide in cacodylate buffer, en bloc stained with 1% aqueous uranyl acetate, dehydrated with 565 acetone and embedded in Epon-Araldite resin (Electron Microscopy Sciences). Samples were flat-566 embedded between two Teflon-coated glass microscope slides and the resin polymerized at 60 °C 567 for 24 h. Embedded tissue blocks were observed by light microscopy to ascertain preservation 568 quality and select regions of interest (i.e., apical epithelium). Blocks were extracted with a scalpel 569 and glued to plastic sectioning stubs prior to sectioning. Semi-thin (150 nm) serial sections were 570 cut with a UC6 ultramicrotome (Leica Microsystems) using a diamond knife (Diatome, Ltd. 571 Switzerland). Sections were placed on formvar-coated copper-rhodium slot grids (Electron 572

Microscopy Sciences) and stained with 3% uranyl acetate and lead citrate. Ig titres at 1.3 months. j, Anti-RBD IgG titres at 6.2 months plotted against anti-N total Ig titres at 668 6.2 months. k, Anti-RBD IgM titres at 1.3 months plotted against anti-N total Ig titres at 1.3 669 months. l, Anti-RBD IgM titres at 6.2 months plotted against anti-N total Ig titres at 6.2 months. 

Convergent antibody responses to SARS-CoV-2 in convalescent 803 individuals

Persistent 805 Symptoms in Patients After Acute COVID-19

Long-term Health Consequences of COVID-19. 1-2, 808

SARS-CoV-2 antibody characterization in emergency department, 810 hospitalized and convalescent patients by two semi-quantitative immunoassays

Elecsys Anti-SARS-CoV-2

Measuring SARS-CoV-2 neutralizing antibody activity using 815 pseudotyped and chimeric viruses

Robust neutralizing antibodies to SARS-CoV-2 infection persist for 818 months

Longitudinal observation and decline of neutralizing antibody responses in 820 the three months following SARS-CoV-2 infection in humans

Potent neutralizing antibodies from COVID-19 patients define 823 multiple targets of vulnerability

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-826

Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-831 Neutralizing Antibodies from COVID-19 Patients

Analysis of a SARS-CoV-2-Infected Individual Reveals Development 834 of Potent Neutralizing Antibodies with Limited Somatic Mutation

Structural basis of a shared antibody response to SARS-CoV-2

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 839 variants

SARS-CoV-2 neutralizing antibody structures inform therapeutic 841 strategies

Ultrapotent human antibodies protect against SARS-CoV-2 843 challenge via multiple mechanisms

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 846 mutational escape seen with individual antibodies

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity

SARS-CoV-2 productively infects human gut enterocytes

Gastrointestinal involvement attenuates COVID-19 severity and 853 mortality. medRxiv

Direct evidence of active SARS-CoV-2 replication in the intestine

Identification of SARS-CoV-2 Inhibitors using Lung and Colonic 857

Incidence and Persistence of Viral Shedding in COVID-19 Post-acute 859

Patients With Negativized Pharyngeal Swab: A Systematic Review

Detection of SARS-CoV-2 in Fecal Samples From Patients With 862 Asymptomatic and Mild COVID-19 in Korea

Virological assessment of hospitalized patients with COVID-2019. 865

Decline of Humoral Responses against SARS-CoV-2 Spike 867 in Convalescent Individuals

Dynamics of neutralizing antibody titers in the months after 869 SARS-CoV-2 infection

Persistence and decay of human antibody responses to the receptor 871 binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Longitudinal dynamics of the neutralizing antibody response to SARS-874

CoV-2 infection

Longitudinal analysis of serology and neutralizing antibody levels in 876 COVID19 convalescents

Antibody potency, effector function and combinations in protection 879 from SARS-CoV-2 infection in vivo

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance 882 of Low Prevalence Communities and Reveal Durable Humoral Immunity

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 885 spike

Potently neutralizing and protective human antibodies against SARS-887

Human B Cell Clonal Expansion and Convergent Antibody 889 Responses to SARS-CoV-2

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal 892 Centers in COVID-19

Evaluation of clinical methods for rating dyspnea

SARS-CoV-2 viral load predicts COVID-19 mortality. The Lancet. 898 Respiratory medicine 8, e70

Single-step method of RNA isolation by acid guanidinium 900 thiocyanate-phenol-chloroform extraction

Solid-phase reversible immobilization 903 for the isolation of PCR products

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans 906 with COVID-19 Disease and Unexposed Individuals

A serological assay to detect SARS-CoV-2 seroconversion in humans

Structures of Human Antibodies Bound to SARS-CoV-2 Spike 911

Reveal Common Epitopes and Recurrent Features of Antibodies

Measuring SARS-CoV-2 neutralizing antibody activity using 914 pseudotyped and chimeric viruses

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 916 variants

Change-O: a toolkit for analyzing large-scale B cell immunoglobulin 918 repertoire sequencing data

High frequency of shared clonotypes in human B cell receptor repertoires. 921

Rep: A Database of 923

Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody 924

A simple method for displaying the hydropathic character of a 926 protein

Amino acid side-chain partition energies and distribution of residues in 928 soluble proteins

A Public Database of Memory and Naive B-Cell Receptor 931 Sequences

Inhibition of Beta interferon induction by severe acute respiratory 933 syndrome coronavirus suggests a two-step model for activation of interferon regulatory 934 factor 3

Automated electron microscope tomography using robust prediction 936 of specimen movements

Automated tilt series alignment and tomographic 938 reconstruction in IMOD

Correction for non-perpendicularity of beam and tilt axis in 941 tomographic reconstructions with the IMOD package

Molecular Architecture of the SARS-CoV-2 Virus

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

SARS-CoV-2 structure and replication characterized by in situ cryo-948 electron tomography. bioRxiv

In situ structural analysis of SARS-CoV-2 spike reveals flexibility 950 mediated by three hinges